A pioneering study uncovers crucial immune dynamics in hepatitis B, offering new insights into how immune responses evolve ...

With an ever increasing number of patients being treated with IVIg for a wide array of immune-mediated disease, it is important that passive antibody transfer is considered when unexpected ...

TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

08036 Barcelona, Catalonia, Spain; rcervera{at}clinic.ub.es Many infections have been found to be associated with antiphospholipid antibodies (aPL), although a pathogenic role for these antibodies has ...